These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37909435)

  • 1. Current Strategy of Monoclonal Antibody: Development, Cloning, Formulation and Drug Delivery.
    Kaliyaperumal R; Ranganathan S; Krishnamoorthy M; Mohan VK; Balaraman S; Rajapandian G; Sathiyasundar R; Ravindran S
    Recent Adv Drug Deliv Formul; 2023; 17(4):264-285. PubMed ID: 37909435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibodies: formulations of marketed products and recent advances in novel delivery system.
    Cui Y; Cui P; Chen B; Li S; Guan H
    Drug Dev Ind Pharm; 2017 Apr; 43(4):519-530. PubMed ID: 28049357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential therapeutic antibodies targeting specific adiponectin isoforms in rheumatoid arthritis.
    Lee YA; Hahm DH; Kim JY; Sur B; Lee HM; Ryu CJ; Yang HI; Kim KS
    Arthritis Res Ther; 2018 Oct; 20(1):245. PubMed ID: 30376894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging trends and therapeutic applications of monoclonal antibodies.
    Mekala JR; Nalluri HP; Reddy PN; S B S; N S SK; G V S D SK; Dhiman R; Chamarthy S; Komaragiri RR; Manyam RR; Dirisala VR
    Gene; 2024 Oct; 925():148607. PubMed ID: 38797505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug delivery systems--2. Site-specific drug delivery utilizing monoclonal antibodies.
    Ranade VV
    J Clin Pharmacol; 1989 Oct; 29(10):873-84. PubMed ID: 2687335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Production of monoclonal antibodies for therapeutic purposes: A review.
    Alejandra WP; Miriam Irene JP; Fabio Antonio GS; Patricia RR; Elizabeth TA; Aleman-Aguilar JP; Rebeca GV
    Int Immunopharmacol; 2023 Jul; 120():110376. PubMed ID: 37244118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging therapeutic role of antibody mixtures.
    Robak T
    Expert Opin Biol Ther; 2013 Jul; 13(7):953-8. PubMed ID: 23646883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal Antibodies: A Review.
    Singh S; Kumar NK; Dwiwedi P; Charan J; Kaur R; Sidhu P; Chugh VK
    Curr Clin Pharmacol; 2018; 13(2):85-99. PubMed ID: 28799485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies for overcoming the biological barriers associated with the administration of inhaled monoclonal antibodies for lung diseases.
    Matera MG; Calzetta L; Rinaldi B; Cazzola M; Rogliani P
    Expert Opin Drug Deliv; 2023; 20(8):1085-1095. PubMed ID: 37715502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Target therapy of cancer: implementation of monoclonal antibodies and nanobodies.
    Majidi J; Barar J; Baradaran B; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(3):81-100. PubMed ID: 19729803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal construction of non-immune scFv phage display libraries from mouse bone marrow and spleen established to select specific scFvs efficiently binding to antigen.
    Okamoto T; Mukai Y; Yoshioka Y; Shibata H; Kawamura M; Yamamoto Y; Nakagawa S; Kamada H; Hayakawa T; Mayumi T; Tsutsumi Y
    Biochem Biophys Res Commun; 2004 Oct; 323(2):583-91. PubMed ID: 15369791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of therapeutic antibodies for the treatment of diseases.
    Lu RM; Hwang YC; Liu IJ; Lee CC; Tsai HZ; Li HJ; Wu HC
    J Biomed Sci; 2020 Jan; 27(1):1. PubMed ID: 31894001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Monoclonal Antibodies: What Headache Specialists Need to Know.
    Silberstein S; Lenz R; Xu C
    Headache; 2015 Sep; 55(8):1171-82. PubMed ID: 26316307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current status and prospect for future advancements of long-acting antibody formulations.
    Tyagi P; Harper G; McGeehan P; Davis SP
    Expert Opin Drug Deliv; 2023; 20(7):895-903. PubMed ID: 37249542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal Antibodies Against Infectious Microbes:
    Raj GM; Priyadarshini R; Murugesan S; Adhimoolam M
    Infect Disord Drug Targets; 2021; 21(1):4-27. PubMed ID: 32164518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibodies and associates: Partners in targeted drug delivery.
    Kennedy PJ; Oliveira C; Granja PL; Sarmento B
    Pharmacol Ther; 2017 Sep; 177():129-145. PubMed ID: 28315359
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging concepts for the treatment of hematological malignancies with therapeutic monoclonal antibodies.
    Capietto AH; Keirallah S; Gross E; Dauguet N; Laprévotte E; Jean C; Gertner-Dardenne J; Bezombes C; Quillet-Mary A; Poupot M; Ysebaert L; Laurent G; Fournié JJ
    Curr Drug Targets; 2010 Jul; 11(7):790-800. PubMed ID: 20370648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapy of haematological malignancies.
    Dearden C
    BioDrugs; 2002; 16(4):283-301. PubMed ID: 12196040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.